Ascendis Pharma price target raised to $254 by Cantor Fitzgerald
PositiveFinancial Markets

Cantor Fitzgerald has raised its price target for Ascendis Pharma to $254, reflecting confidence in the company's growth potential and upcoming product developments. This adjustment is significant as it indicates strong market optimism and could attract more investors, ultimately benefiting the company's stock performance.
— Curated by the World Pulse Now AI Editorial System